- Home
- CURX vs CRDL Comparison
CURX vs CRDL Comparison
Compare CURX & CRDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CURX
- CRDL
- Stock Information
- Founded
- CURX 2018
- CRDL 2017
- Country
- CURX United States
- CRDL Canada
- Employees
- CURX N/A
- CRDL N/A
- Industry
- CURX Biotechnology: Pharmaceutical Preparations
- CRDL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CURX Health Care
- CRDL Health Care
- Exchange
- CURX Nasdaq
- CRDL Nasdaq
- Market Cap
- CURX 155.4M
- CRDL 126.5M
- IPO Year
- CURX 2025
- CRDL N/A
- Fundamental
- Price
- CURX $7.10
- CRDL $1.11
- Analyst Decision
- CURX
- CRDL Strong Buy
- Analyst Count
- CURX 0
- CRDL 2
- Target Price
- CURX N/A
- CRDL $9.00
- AVG Volume (30 Days)
- CURX 3.9M
- CRDL 1.2M
- Earning Date
- CURX 01-01-0001
- CRDL 08-14-2025
- Dividend Yield
- CURX N/A
- CRDL N/A
- EPS Growth
- CURX N/A
- CRDL N/A
- EPS
- CURX N/A
- CRDL N/A
- Revenue
- CURX N/A
- CRDL N/A
- Revenue This Year
- CURX N/A
- CRDL N/A
- Revenue Next Year
- CURX N/A
- CRDL N/A
- P/E Ratio
- CURX N/A
- CRDL N/A
- Revenue Growth
- CURX N/A
- CRDL N/A
- 52 Week Low
- CURX $3.61
- CRDL $0.77
- 52 Week High
- CURX $7.29
- CRDL $2.63
- Technical
- Relative Strength Index (RSI)
- CURX N/A
- CRDL 43.82
- Support Level
- CURX N/A
- CRDL $1.12
- Resistance Level
- CURX N/A
- CRDL $1.19
- Average True Range (ATR)
- CURX 0.00
- CRDL 0.08
- MACD
- CURX 0.00
- CRDL -0.00
- Stochastic Oscillator
- CURX 0.00
- CRDL 13.89
About CRDL Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's main product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.